A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.

[1]  J. Carles,et al.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.

[2]  F. Saad,et al.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. , 2022, The New England journal of medicine.

[3]  C. Porta,et al.  Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. , 2021, European Journal of Cancer.

[4]  M. Climent,et al.  SEOM clinical guidelines for the treatment of advanced prostate cancer (2020) , 2021, Clinical and Translational Oncology.

[5]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Egawa,et al.  Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy , 2019, The world journal of men's health.

[7]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[8]  M. Borre,et al.  Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[10]  F. Saad,et al.  Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 , 2016, European urology.

[11]  D. Petrylak,et al.  Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[12]  J. Burke,et al.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. , 2015, The Lancet. Oncology.

[13]  E. Antonarakis,et al.  Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Giannakakou,et al.  Androgen receptor on the move: boarding the microtubule expressway to the nucleus. , 2012, Cancer research.

[15]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.